Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) (Q34461279)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) (English)

1 reference

Europe PubMed Central

2 August 2017

hypercholesterolemia

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Jones P

1

1 reference

Europe PubMed Central

2 August 2017

Kafonek S

2

1 reference

Europe PubMed Central

2 August 2017

Laurora I

3

1 reference

Europe PubMed Central

2 August 2017

Hunninghake D

4

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

1 March 1998

1 reference

Europe PubMed Central

2 August 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

2 August 2017

81

1 reference

Europe PubMed Central

2 August 2017

582-587

1 reference

Europe PubMed Central

2 August 2017

5

1 reference

Europe PubMed Central

2 August 2017

Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900965-X

7 January 2021

Identifiers

10.1016/S0002-9149(97)00965-X

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34461279&oldid=1617937458"